EFG Asset Management North America Corp. Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

EFG Asset Management North America Corp. raised its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 58.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 82,818 shares of the company's stock after purchasing an additional 30,608 shares during the quarter. EFG Asset Management North America Corp. owned 0.16% of Spyre Therapeutics worth $1,929,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in SYRE. Barclays PLC boosted its holdings in shares of Spyre Therapeutics by 64.7% during the third quarter. Barclays PLC now owns 105,467 shares of the company's stock worth $3,101,000 after purchasing an additional 41,424 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Spyre Therapeutics in the 4th quarter worth approximately $290,000. Charles Schwab Investment Management Inc. grew its position in shares of Spyre Therapeutics by 239.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company's stock worth $9,802,000 after buying an additional 235,094 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Spyre Therapeutics in the 4th quarter worth approximately $6,241,000. Finally, Jane Street Group LLC increased its stake in shares of Spyre Therapeutics by 78.7% during the third quarter. Jane Street Group LLC now owns 20,641 shares of the company's stock valued at $607,000 after buying an additional 9,090 shares during the period. Institutional investors own 80.39% of the company's stock.

Spyre Therapeutics Price Performance

Spyre Therapeutics stock traded up $0.25 during mid-day trading on Friday, reaching $17.94. 623,872 shares of the stock traded hands, compared to its average volume of 556,154. Spyre Therapeutics, Inc. has a 12-month low of $16.71 and a 12-month high of $40.84. The business's 50-day moving average is $20.54 and its 200-day moving average is $25.58. The stock has a market capitalization of $1.08 billion, a PE ratio of -2.40 and a beta of 2.98.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.08. Equities analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Wolfe Research began coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price on the stock. Finally, The Goldman Sachs Group raised shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $50.33.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).